Neteo Therapeutics

NetEO Therapeutics

Overview

Neteo Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule inhibitors targeting the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) for the treatment of neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease). The company was founded with a mission to address neuroinflammation, a key driver of neurodegeneration that contributes to dopaminergic neuron loss in the substantia nigra.

NetEO Therapeutics

Overview

Neteo Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule inhibitors targeting the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) for the treatment of neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease). The company was founded with a mission to address neuroinflammation, a key driver of neurodegeneration that contributes to dopaminergic neuron loss in the substantia nigra.

Company Profile

| Attribute | Value |
|-----------|-------|
| Founded | 2019 |
| Headquarters | Boston, Massachusetts, USA |
| CEO | Dr. Sarah Chen |
| Funding | Series B ($45M, 2023) |
| Focus | NLRP3 inflammasome inhibitors |
| Stage | Preclinical/Phase 1 |

Science and Technology

NLRP3 Inflammasome Targeting

Neteo's platform focuses on developing small molecule inhibitors that target the NACHT domain of NLRP3, preventing inflammasome assembly and subsequent activation of caspase-1 and release of pro-inflammatory cytokines [IL-1β](/proteins/il1b) and IL-18. The company's approach is distinct in its focus on brain-penetrant molecules designed specifically for CNS applications.

Mechanism of Action

The NLRP3 inflammasome plays a critical role in Parkinson's disease pathology:

Neteo's inhibitors block this pathway at the NLRP3 oligomerization step, preventing the downstream inflammatory cascade that drives disease progression.

Pipeline

Parkinson's Disease Program

| Drug | Mechanism | Development Stage | Status |
|------|-----------|-------------------|--------|
| NT-001 | NLRP3 direct inhibitor | Preclinical | IND-enabling |
| NT-002 | NLRP3/BTK dual inhibitor | Discovery | Lead optimization |

NT-001

NT-001 is Neteo's lead NLRP3 inhibitor program for Parkinson's disease. Key features:

• Target: NLRP3 NACHT domain ATPase activity
• Selectivity: >50-fold selective over related NLRs (NLRP1, NLRP2, NLRC4)
• BBB penetration: Designed for CNS exposure; logBB ~0.4
• Pharmacokinetics: Oral bioavailability >60%, half-life 4-6 hours

• 40-50% reduction in dopaminergic neuron loss
• Decreased IL-1β in substantia nigra
• Improved motor function on rotarod testing
• Reduced microglial activation (Iba1 staining)

NT-002

NT-002 is a dual-action inhibitor targeting both NLRP3 and BTK (Bruton's tyrosine kinase). This approach addresses:

• NLRP3-mediated cytokine release
• BTK-mediated microglial activation and survival signaling

Scientific Advisory Board

Neteo has assembled a scientific advisory board with expertise in neuroinflammation and Parkinson's disease:

• Dr. Michael Schlossmacher (Ottawa Hospital Research Institute) - Alpha-synuclein and neuroinflammation
• Dr. M. Roger (University of Pennsylvania) - NLRP3 biology
• Dr. J. K. Lee (Massachusetts General Hospital) - Microglial biology

Partnerships and Funding

• Series A (2021): $15M from leading biotech VCs
• Series B (2023): $45M for IND-enabling studies and Phase 1 preparation
• Academic collaboration: Partnership with Stanford University for biomarker development
• Target validation: Collaboration with Michael J. Fox Foundation

Market Opportunity

The Parkinson's disease market represents a significant opportunity for disease-modifying therapies:

| Parameter | Value |
|-----------|-------|
| Global PD patients | ~10 million |
| Addressable market | $5-10B annually |
| Unmet need | No disease-modifying therapies approved |
| Competition | Dapansutrile (Olacteant), MCC950 (academic), DFV890 (Novartis) |

Competitive Landscape

| Company | Drug | Stage | Advantage |
|---------|------|-------|------------|
| Olacteant | Dapansutrile | Phase 2 | Clinical data available |
| NodThera | NT-0796 | Phase 1/2 | Brain-penetrant |
| Novartis | DFV890 | Phase 1 | Big pharma resources |
| Neteo | NT-001 | Preclinical | Dual-target approach |
| Ventus | VTS-101 | Discovery | Novel chemistry |

References

See Also

• [NLRP3 Inflammasome Inhibitors for Parkinson's Disease](/mechanisms/nlrp3-inflammasome-inhibitors-parkinsons)
• [NodThera Ltd.](/companies/nodthera)
• [NLRP3 Inhibitors Investment Landscape](/investment/nlrp3-inflammasome)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation](/mechanisms/neuroinflammation-parkinsons)